Episode 18: A Between the Biotech Waves conversation with Ram Aiyer, CEO of RNA base editing company Korro Bio
Between the Biotech Waves
00:00
Is There a Tough Spot for a Board?
I think that when somebody's not doing the actual operational side on a day to day basis, and the underpinning with respect to how tough these things actually are, there is an expectation that things will go faster than invariably they actually go. And I'm sure you're tired of getting calls from various investors to around saying, hey, I thought we'd have X, Y, or Z by now, what's taken so long, why isn't it happening? And so that's got to be challenging. The board is actually pretty good versus maybe some of the other boards I've been involved with historically is being comfortable enough to let you drive," he said.
Transcript
Play full episode
